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Abstract
Background: No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital
mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia.
Methods: This was a multicenter, retrospective, cohort study of patients with methicillin-resistant Staphylococcus
aureus bacteremia receiving at least 48 hours of empiric vancomycin therapy between 01/07/2002 and 30/06/2008.
We compared in-hospital mortality for patients treated empirically with weight-based, guideline-recommended
vancomycin doses (at least 15 mg/kg/dose) to those treated with less than 15 mg/kg/dose. We used a general
linear mixed multivariable model analysis with variables identified a priori through a conceptual framework based
on the literature.
Results: A total of 337 patients who were admitted to the three hospitals were included in the cohort. One-third of
patients received vancomycin empirically at the guideline-recommended dose. Guideline-recommended dosing
was not associated with in-hospital mortality in the univariable (16% vs. 13%, OR 1.26 [95%CI 0.67-2.39]) or
multivariable (OR 0.71, 95%CI 0.33-1.55) analysis. Independent predictors of in-hospital mortality were ICU admission,
Pitt bacteremia score of 4 or greater, age 53 years or greater, and nephrotoxicity.
Conclusions: Empiric use of weight-based, guideline-recommended empiric vancomycin dosing was not
associated with reduced mortality in this multicenter study.
Keywords: Weight, Obesity, Efficacy, MRSA, Vancomycin, Bacteremia
Background
Vancomycin is commonly used for the treatment of methi-
cillin-resistant Staphylococcus aureus (MRSA) bacteremia.
The United States of America Food and Drug Administra-
tion (FDA) originally approved a dosing regimen of 1 gram
administered intravenously (IV) every 12 hours (or
500 mg IV every six hours). The FDA approved dosing
regimen has not changed in over 50 years despite several
studies demonstrating that vancomycin pharmacokinetics
in adults are best predicted by actual body weight [1-4].
Dosing handbooks that are used in clinical practice con-
tinue to recommend a fixed dose for all patients regardless
of weight [5,6].
Over the past decade, there has been an increase in the
incidence of MRSA strains with vancomycin minimum in-
hibitory concentration (MIC) values≥ 1 μg/ml as well as
heteroresistant vancomycin-intermediate S. aureus. In re-
sponse to increasing vancomycin MICs in MRSA isolates,
the Infectious Diseases Society of America, the American
of Society of Health-Systems Pharmacists, and the Society
of Infectious Diseases Pharmacists developed weight-based
dosing recommendations for vancomycin based on phar-
macokinetic and pharmacodynamic data (15–20 mg/kg/
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dose IV administered every eight to 12 hours) [7]. The
clinical effectiveness of this empiric weight-based, guide-
line-recommended dosing regimen (at least 15 mg/kg/
dose) has yet to be critically evaluated.
Data evaluating guideline-recommended weight-based
vancomycin dosing are needed to confirm the efficacy of
this approach versus lower traditional dosing. Therefore,
we conducted a multicenter retrospective cohort study
to evaluate the effectiveness of guideline-recommended
weight-based dosing for vancomycin on mortality of
patients with MRSA bacteremia.
Methods
Study location and patients
We identified a retrospective cohort of patients admitted
with MRSA bacteremia (using microbiological records)
between 01/07/2002 and 30/06/2008 at three types of
hospitals (400 bed urban, 200 bed veteran affairs, and
604 bed university). Patients were included if they were
at least 18 years old and had received parenteral vanco-
mycin for at least 48 hours. Patients were excluded if, at
the time of the first vancomycin dose, they were receiving
dialysis, had a creatinine clearance of 30 ml/min or less
based upon the Cockcroft-Gault equation, received prior
vancomycin within the hospital stay, had a culture-proven
MRSA infection in the previous six months, or were preg-
nant [8]. The institutional review board of each respective
site (North Texas Veterans Health Care System, Texas
Tech University Health Sciences Center, and University of
Texas Health Science Center, San Antonio) approved the
study and waived the need for informed consent.
Study design and data collection
We conducted a retrospective cohort study of patients
who received guideline-recommended weight-based dos-
ing with those receiving lower dosing of vancomycin for
MRSA bacteremia. Our primary outcome was in-hos-
pital mortality.
Study definitions
All definitions were selected prospectively during the
initial trial design. Guideline-recommended weight-
based dosing was defined as at least 30 mg/kg/day in the
first 24 hours (at least 15 mg/kg/day for patients with a
creatinine clearance of 30–50 ml/min). Lower dosing
was defined as receiving less than 30 mg/kg/day (less
than 15 mg/kg/day for patients with a creatinine clear-
ance of 30–50 ml/min). Pitt bacteremia score was calcu-
lated based on the date when the first positive blood
culture was obtained [9,10]. In-hospital mortality was
defined as patient death occurring within the index hos-
pital stay. Nephrotoxicity was defined as an increase in cre-
atinine by more than 0.5 mg/dl or greater than a 50%
increase from baseline on two consecutive days [7].
Statistical analysis
Recursive partitioning was used to ascertain signifi-
cant cut-points in continuous candidate variables
associated with an increased risk of mortality [11].
Univariable associations were explored using either
Chi-square or Fisher’s Exact tests. A Pitt bacteremia
score cutoff of 4 or higher was used based on previ-
ous literature demonstrating significantly higher sensi-
tivity and specificity for predicting severity of illness
[12]. A vancomycin trough 15 mcg/ml or greater was
based on the guideline recommended trough concen-
tration range of 15–20 mcg/ml [7]. Variables exam-
ined in the initial univariable analysis included receipt
of guideline recommended weight-based vancomycin
dosing, intensive care unit (ICU) admission, age
53 years, Pitt bacteremia score of 4 or higer, vanco-
mycin trough 15 mcg/ml or greater, nephrotoxicity,
Charlson comorbidity index score of 5 or higher,
weight of 100 kg or greater, and gender.
Variables identified as significant through univari-
able analysis (p< 0.1) and those conceptually regarded
as biologically reasonable causes of mortality were
considered for inclusion in the multivariable model. A
generalized linear mixed-effect model was utilized to
identify independent predictors of mortality. Hospital
site was treated as a random effect whereas other
covariates were treated as fixed effects. Variables were
retained in the multivariable model if their respective
p values were< 0.05. Adjusted ORs and 95% confi-
dence intervals were calculated for each variable. Ef-
fect measure modification and biologic interaction
were also extensively evaluated. All analyses were per-
formed using SAS 9.2 (Cary, North Carolina) and




A total of 798 patients with MRSA bacteremia were evalu-
ated, with 337 included in the study cohort after applica-
tion of the exclusion criteria. In-hospital mortality data
were not collected for one patient. The baseline character-
istics of the cohort are shown in Table 1. Forty-seven
patients (14%) died during their hospital stay. Survivors
were more likely to be male and less likely to have vanco-
mycin started in the ICU (34 vs. 83%). Survivors also had a
younger median age, higher baseline renal function, lower
Charlson Comorbidity Index, and a less severe Pitt
Bacteremia score. Vancomycin was empirically dosed
according to guidelines in 33% of survivors and 38% of
non-survivors (p = 0.48) with a median initial daily dose
of 24.9 vs. 21.0 mg/kg/day (p = 0.036), respectively.
Vancomycin was adjusted for renal function in 39% of
survivors and 59% of non-survivors (p = 0.028).
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The primary sources of bacteremia were skin/soft tissue
(32.5%), intravenous catheter (20.2%), and pulmonary
(17.8%). Other documented sources included genitourinary
(8%), bone (1.2%), gastrointestinal (0.5%), and central
nervous system (0.3%). The source of bacteremia was
not specified for 19.8% of patients. Non-survivors were less
likely to have a skin/muscle source of their bacteremia and
more likely to have a bloodstream catheter-related or pul-
monary source. Seventy-nine patients (23.4%) received
concomitant antimicrobials active against MRSA. Non-sur-
vivors were less likely to receive IV contrast dye and more
likely to receive vasopressors. Nineteen percent of both
groups received aminoglycosides. Nephrotoxicity occurred
in 82 patients (23.4%).
The overall median (interquartile range) length of hos-
pital stay was 16 (9, 32) days for survivors and 23 (14, 56)
for non-survivors (p=0.009). The median length of stay
after vancomycin initiation was 14 (7.5, 26.5) days for
survivors and 19 (9, 42) for non-survivors. Thirty-two per-
cent of patients had a hospital stay longer than 28 days.
The median ICU length of stay was 0 (0, 4) days for survi-
vors and 9 (3, 39) for non-survivors.
Univariable and multivariable analysis
In the univariable analysis (Table 2), mortality was similar
among patients who received guideline-recommended
dosing versus lower dosing (16% vs. 13%, OR 1.26 [95%CI
0.67-2.39]). Factors that increased risk for mortality by
univariable analysis included: male gender, age of 53 years
or greater, ICU admission, Pitt bacteremia score of four or
greater, nephrotoxicity, and vancomycin trough of 15
mcg/ml or greater.
Vancomycin dosing also was not significantly associated
with mortality (OR 1.05, 95%CI 0.48-2.27) when retained
in the multivariable analysis (Table 3). The only factors
that remained significant in the multivariable model were
Table 1 Baseline characteristics of the cohortA
Characteristic Survivors (n = 289) Non-survivors (n = 47) p-value
Male gender (%) 77% 94% 0.009
Age (years) 53 (42, 63) 65 (56, 77) <0.001
Race (%) 0.66
Caucasian 64% 74%
African American 15% 11%
Hispanic 18% 13%
Other 3% 2%
Height (cm) 175.0 (165.1, 180.3) 175.0 (169.5, 183.0) 0.14
Weight (kg) 78.1 (65, 95.6) 80.0 (63.0, 99.0) 0.91
Serum Creatinine (mg/dl) 0.90 (0.7, 1.2) 1.10 (0.7, 1.5) 0.035
Creatinine Clearence (ml/min) 86.9 (61.0, 122) 64.0 (42.9, 86.3) <0.001
Pitt Bacteremia Score 1 (0, 3) 3 (2, 6) <0.001
Charlson Comorbidity Index 2 (1, 3) 2 (2, 4) 0.030
Guideline-recommended Vancomycin Dose Received (%) 33% 38% 0.48
Dose adjusted for renal function (%) 39% 59% 0.028
Vancomycin Started in Intensive Care Unit (%) 34% 83% <0.001
Initial Vancomycin Dose (mg/kg/day) 24.9 (19.6, 30.4) 21.0 (17.0, 29.0) 0.036
Nephrotoxins (%)
Intravenous Contrast 34% 13% 0.004
Aminoglycosides 19% 19% 0.98
Vasopressors 7% 36% <0.001
Infection source (%) <0.001
Bloodstream catheter-related 18% 36%






A=Results are presented as median (interquartile range) unless otherwise noted.
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age of 53 years or greater, ICU admission, Pitt bacteremia
score of four or greater, and nephrotoxicity.
Discussion
To our knowledge, this is the first published multicen-
ter study to evaluate the effect of empiric guideline-
recommended weight-based dosing on mortality in
MRSA bacteremia. We did not observe any significant
relationship between empiric guideline-recommended
weight-based vancomycin dosing and in-hospital mor-
tality. Independent predictors of in-hospital mortality
were ICU admission, Pitt bacteremia score of 4 or
greater, age 53 years or greater, and nephrotoxicity.
Most studies evaluating the effectiveness of vanco-
mycin dosing for MRSA infections have compared high
vs. low vancomycin trough concentrations. Our results
parallel the findings of these studies. A recently pub-
lished prospective cohort study assessing patients with
MRSA pneumonia and bacteremia failed to demonstrate
that achieving vancomycin trough concentrations to 4 to
5 times the MIC were associated with any difference in
clinical response rates [13]. Another study of 102 patients
evaluated the association between vancomycin trough
concentrations and mortality in MRSA pneumonia; 11%
of patients had concomitant bacteremia [14]. This study
did not find a difference in vancomycin trough concen-
trations between survivors and non-survivors (13.6 vs.
13.9 mcg/ml). Using vancomycin trough concentrations
to evaluate mortality is potentially confounded by the
fact that vancomycin is eliminated by the kidneys. Acute
renal failure is an independent risk factor for mortality,
which also results in increased vancomycin trough con-
centrations (regardless of the cause of acute renal
failure).
Our findings suggest that other patient factors play
are more important factors in determining in-hospital
mortality for patients with MRSA bacteremia than vanco-
mycin dosing. The empiric use of guideline-recommended
weight-based dosing in the absence of compelling efficacy
or effectiveness data has the potential to place patients at
an increased risk of concentration-related adverse events
with an uncertain benefit to the patient. Clinicians should
critically evaluate vancomycin trough concentrations and
kidney function to help minimize this risk in patients re-
ceiving guideline-recommended weight-based vancomycin
regimens.
The implications of this study on clinical practice are
limited by its retrospective design, use of in-hospital
mortality, lack of MIC data, and lack of data regarding
time to a therapeutic vancomycin trough concentration.
Utilizing in-hospital mortality as our primary endpoint
resulted in fewer events than utilizing 30 day mortality
or vancomycin failure [15-17]. This difference created
greater variability in the multivariable model and limited
the number of candidate variables evaluated in the mul-
tivariable model. In spite of this limitations, the factors
associated with mortality in this study are similar to
others [15]. The study’s retrospective design allowed a
more realistic estimate of clinical effectiveness than
could be observed in a randomized, controlled trial.
Increased vancomycin MIC values may have also played
a role in the lack of benefit associated with guideline-
recommended dosing. However, clinicians rarely have
vancomycin MIC data available when selecting an em-
piric vancomycin dose. We did not collect data regard-
ing the time to the first therapeutic vancomycin trough,
as quicker times to therapeutic trough concentrations
may improve vancomycin efficacy. However, this infor-
mation may have been biased in this retrospective evalu-
ation by clinician judgment regarding when trough
concentrations were ordered. Our results may have also
been subject to a selection bias that patients weighing
greater than 70 kilograms were less likely to receive
guideline-recommended, weight-based vancomycin dos-
ing since most patients (85%) received 1 gram every 12
hours. Furthermore, the implications of loading doses on
Table 3 Multivariable analysis of independent risk factors
for mortality





Intensive Care Unit Admission 6.14 2.46-15.35
Age of 53 years or greater 5.58 1.88-16.51





15 mcg/ml or greater
1.24 0.56-2.75
Table 2 Univariable analysis of risk factors for mortality





Intensive Care Unit Admission 9.50 4.27-21.12
Age of 53 years or greater 7.89 3.04-20.52








of five or greater
1.63 0.75-3.54
Weight of 100 kg or greater 1.14 0.55-2.37
Male gender 4.43 1.33-14.71
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mortality need further evaluation since none of the study
institutions utilized this dosing strategy.
Conclusions
In our study, we did not observe any significant associ-
ation between guideline-recommended dosing and mor-
tality. These results, in concert with the findings of
others, call for a prospective, randomized comparison of
empiric use of guideline-recommended weight-based vs.
traditional dosing of vancomycin to ensure that patients
treated with vancomycin receive doses that maximize ef-
ficacy and safety.
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